AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO – Get Rating) shares crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $4.52 and traded as high as $4.66. AVEO Pharmaceuticals shares last traded at $4.50, with a volume of 251,433 shares trading hands.
A number of analysts have recently issued reports on the stock. Jonestrading assumed coverage on shares of AVEO Pharmaceuticals in a research note on Monday, March 14th. They set a “buy” rating for the company. StockNews.com initiated coverage on shares of AVEO Pharmaceuticals in a research note on Thursday, March 31st. They set a “hold” rating for the company.
The company has a quick ratio of 4.73, a current ratio of 4.81 and a debt-to-equity ratio of 1.03. The firm has a fifty day moving average of $4.54 and a two-hundred day moving average of $4.51.
A number of institutional investors have recently made changes to their positions in AVEO. AIGH Capital Management LLC raised its holdings in AVEO Pharmaceuticals by 28.7% in the fourth quarter. AIGH Capital Management LLC now owns 2,556,600 shares of the biopharmaceutical company’s stock worth $11,990,000 after purchasing an additional 570,424 shares in the last quarter. Millennium Management LLC raised its holdings in AVEO Pharmaceuticals by 28.3% in the fourth quarter. Millennium Management LLC now owns 899,968 shares of the biopharmaceutical company’s stock worth $4,221,000 after purchasing an additional 198,693 shares in the last quarter. Worth Venture Partners LLC increased its holdings in shares of AVEO Pharmaceuticals by 20.5% during the first quarter. Worth Venture Partners LLC now owns 705,154 shares of the biopharmaceutical company’s stock valued at $3,942,000 after acquiring an additional 119,986 shares in the last quarter. Sender Co & Partners Inc. acquired a new position in shares of AVEO Pharmaceuticals during the fourth quarter valued at about $432,000. Finally, J. Goldman & Co LP increased its holdings in shares of AVEO Pharmaceuticals by 7.3% during the first quarter. J. Goldman & Co LP now owns 1,309,966 shares of the biopharmaceutical company’s stock valued at $7,323,000 after acquiring an additional 89,208 shares in the last quarter. Institutional investors and hedge funds own 52.61% of the company’s stock.
About AVEO Pharmaceuticals (NASDAQ:AVEO)
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA.
- Get a free copy of the StockNews.com research report on AVEO Pharmaceuticals (AVEO)
- Ride Out The Recession With These Dividend Kings
- MarketBeat: Week in Review 6/13 – 6/17
- eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
- Honda’s Stock Continues To Fly Under The Radar
- Vuzix Stock Stays Optimistic
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.